drugset / Trial / NCT07221877

A Study to Evaluate the Effect of KarXT on Urological Safety

NCT07221877

Phase 4 Recruiting 60 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

Timeline

Start
2026-01-20
Primary completion
2027-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule
Subject Xanomeline Small molecule

Indications